Rizatriptan

Oral
Acute migraine attacks

Patients taking concomitant propranolol: Initiate with 5 mg. Max: 10-15 mg daily. Ensure that the 2 drugs are separated by at least 2 hours interval.

For mild-moderate impairment, initate with 5 mg. Further dose of 5 mg may be taken after an interval of at least 2 hr. Max: 10 mg/24 hr. Avoid in severe impairment.

For mild-moderate impairment, initate with 5 mg. Further dose of 5 mg may be taken after an interval of at least 2 hr. Max: 10 mg/24 hr. Avoid in severe impairment.

Tab: May be taken with or without food.
Orally-Disintegrating Tab: May be taken with or without food. Place on the tongue & allow to dissolve; it can then be swallowed w/ the saliva.

History of MI, peripheral vascular disease, transient ishaemic attack, ischaemic heart disease or Prinzmetal's angina; uncontrolled hypertension; basilar or hemiplegic migraine; severe hepatic or renal impairment. Adolescent <18 yr.

Elderly; mild to moderate hepatic or renal impairment; coronary artery disease; pregnancy, lactation. May cause drowsiness. History of seizures. Ensure an interval of at least 24 hr after stopping an ergotamine compound and starting a serotonin (5-HT₁) agonist.

Increased BP, chest pain, palpitation; skin flushing; dyspnoea; nausea, abdominal pain, dry mouth; dizziness, drowsiness, fatigue.
Potentially Fatal: Toxic epidermal necrolysis.

PO: C

May cause hypertension and CV symptoms. Gastric lavage using activated charcoal may be considered. Monitor ECG and clinical status of the patient.

Increased serum concentrations with propranolol. Increased risk of vasospastic reactions when used with ergotamine and methysergide. Concurrent use with SSRIs may increase risk of serotonin syndrome.
Potentially Fatal: Concurrent use with or within 2 wk of stopping MAOI treatment.

Absorption delayed. Concurrent use with St John's wort may increase risk of adverse reactions.

Description: Rizatriptan is a selective serotonin (5-HT₁) agonist in cranial arteries responsible for vasoconstriction and reduction of inflammation associated with antidromic neuronal transmission.
Pharmacokinetics:
Absorption: Bioavailability: about 40-45%.
Distribution: Protein binding: 14%.
Metabolism: Primarily by monoamine oxidase type A.
Excretion: About 14% of an oral dose is excreted unchanged in the urine. Plasma half-life: about 2-3 hr.

Store at 15-30°C.

Antimigraine Preparations